The challenge in finding a simple, accurate, reliable, and affordable tool for the objective assessment of excessive daytime sleepiness (EDS)
Abstract
Excessive daytime sleepiness (EDS) refers to a physiological state where individuals have difficulty remaining alert during the day. Managing EDS is particularly challenging to study and treat due to its multifaceted nature. Assessment methods include both subjective and objective approaches. Subjective evaluation often relies on simple, widely accepted, and widely used questionnaires; however, these tools are inherently limited by self-reporting bias. Objective assessment, on the other hand, primarily involves two well-known and reliable tests, but these are costly, time-consuming, and impractical for use outside of sleep units. Therefore, developing an objective tool that can quickly and accurately detect a decline in alertness, while remaining reliable, easy to use, and affordable, is of critical importance for sleep clinicians, safety organizations, and researchers. According to PRISMA guidelines, we did a systematic analysis of 95 studies that used photoplethysmography (PPG) for assessing EDS, drowsiness, and/or fatigue during the last 15 years (2010-2025). With advances in wearable technology, particularly through PPG and artificial intelligence, achieving this goal may be attainable. The next essential step is rigorous validation against established gold-standard tests to ensure the tool meets scientific and clinical standards for widespread adoption.
How strong is the evidence?
Evidence Hub reads this as a systematic review, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.